EGFR and non-small cell lung carcinoma: Given that EGFRi treatment is primarily employed on NSCLC patients with activating mutations within the kinase domain of EGFR, specifically in exon 18–21,6,31 we categorized EGFR mutations into five classes based on their specific location and oncogenic effects as annotated by OncoKB32 (Figure 1C).